CRDF
Cardiff Oncology, Inc.
NASDAQ · Healthcare · Biotechnology · US
$1.09
+0.93%Aug 11, 2026, 20:10 UTC
Cardiff Oncology presented positive Phase 2 CRDF-004 data at ASCO supporting advancement of 30 mg onvansertib plus FOLFIRI/bevacizumab into a planned registrational program for first-line RAS-mutated metastatic colorectal cancer.
Source:Jul 15, 2026, 12:00 UTC
Cardiff Oncology entered into definitive agreements for a registered direct offering of shares of its common stock and warrants.
Source: